|
 Merck & Co's experimental pill molnupiravir is likely to be one of
the drugs, and other drugs to treat mild patients are being
developed.
The document, which outlines the goals of the Access to COVID-19
Tools Accelerator (ACT-A) until September next year, says that the
programme wants to deliver about 1 billion COVID-19 tests to poorer
nations, and procure drugs to treat up to 120 million patients
globally, out of about 200 million new cases it estimates in the
next 12 months.
The plans highlight how the WHO wants to shore up supplies of drugs
and tests at a relatively low price after losing the vaccine race to
wealthy nations which scooped up a huge share of the world's
supplies, leaving the world's poorest countries with few shots.
A spokesperson for the ACT-A said the document, dated Oct. 13, was
still a draft under consultation and declined to comment on its
content before it is finalised. The document will also be sent to
global leaders ahead of a G20 summit in Rome at the end of this
month.
The ACT-A asks the G20 and other donors for additional funding of
$22.8 billion until September 2022 which will be needed to buy and
distribute vaccines, drugs and tests to poorer nations and narrow
the huge gaps in supply between wealthy and less advanced countries.
Donors have so far pledged $18.5 billion to the programme.
The financial requests are based on detailed estimates about the
price of drugs, treatments and tests, which will account for the
programme's biggest expenses alongside the cost of distributing
vaccines.
Although it does not explicitly cite molnupiravir, the ACT-A
document expects to pay $10 dollar per course for "novel oral
antivirals for mild/moderate patients".
Other pills to treat mild patients are being developed, but
molnupiravir is the only one which has so far showed positive
results in late-stage trials. The ACT-A is in talks with Merck & Co
and generics producers to buy the drug.
The price is very low if compared with the $700 per course that the
United States has agreed to pay for 1.7 million courses of the
treatment.
However, a study carried out by Harvard university estimated that
molnupiravir could cost about $20 dollars if produced by generic
drugmakers, with the price potentially going down to $7.7 under an
optimised production.
Merck & Co. has licensing deals with eight Indian generic drugmakers.
The ACT-A document says that its target is to reach a deal by the
end of November to secure the supply of an "oral outpatient drug",
which it aims to be available from the first quarter of next year.
The money raised would initially be used to "support procurement of
up to 28 million treatment courses for highest risk mild/moderate
patients over the next 12 months, depending on product availability,
clinical guidance, and volumes changing with evolution of needs,"
the document says, noting this volume would be secured under an
advance purchase agreement.
[to top of second column] |
 Larger additional amounts of
new oral antivirals to treat mild patients are
also expected to be procured at a later stage,
the document says. Another 4.3
million courses of repurposed COVID-19 pills to treat critical
patients are also expected to be purchased at a price of $28 per
course, the document says, without naming any specific drug.
The ACT-A also intends to address essential medical oxygen needs of
6-8 million severe and critical patients by September 2022.
TESTS
In addition, the programme plans to invest massively in COVID-19
diagnostics in order to at least double the number of tests carried
out in poorer nations, defined as low income and low-middle income
countries.
 Of the $22.8 billion, ACT-A plans to
raise in the next 12 months, about one third and the largest share
is to be spent on diagnostics, the document says.
Currently poor countries conduct on average about 50 tests per
100,000 people every day, against 750 tests in richer nations. The
ACT-A wants to bring testing rates to a minimum of 100 tests per
100,000 in poorer states.
That means delivering around 1 billion tests in the next 12 months,
around 10 times more than the ACT-A has procured so far, the
document shows.
The largest share of diagnostics would be rapid antigen tests at a
price of around $3, and only 15% would be spent to procure molecular
tests, which are more accurate but take more time to deliver results
and are estimated to cost around $17, including delivery costs, the
document shows. The push on tests is meant to narrow
the gap between the rich and the poor, as only 0.4% of the about 3
billion tests reported across the world have been conducted in poor
nations, the document says.
It would also help spot earlier possible new variants, which tend to
proliferate when infections are widespread, and therefore are more
likely in the countries with lower vaccination rates.
The document underlines that "vaccine access is highly inequitable
with coverage ranging from 1% to over 70%, depending largely on a
country's wealth."
The programme aims to vaccinate at least 70% of the eligible
population in all countries by the middle of next year, in line with
the WHO's goals.
(Reporting by Francesco Guarascio @fraguarascio; Editing by Susan
Fenton)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
 |
